ArticlePloS one2026
Mechanism of action of cisplatin on Na+/K+ ATPase of Caco-2 colon cells in vitro.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin is a chemotherapeutic agent that reverts cancerous cells to the apoptotic route. A decrease in the activity of the Na+/K+ ATPase is one of the hallmarks of apoptosis and a major causative factor of the drug-induced nephrotoxicity. Whether cisplatin targets also the colonic ATPase is a question that was addressed in this work using Caco-2 cells as a model. ATPase activity was measured via inorganic phosphate release with and without ouabain, and protein expression was assessed by Western blot. Cisplatin reduced the activity of the Na+/K+ ATPase, an effect that was dependent on the transmembrane chloride gradient but had no effect on the purified enzyme, suggesting an indirect action. Fluorescence imaging showed a decrease in the membrane ATPase abundance. Cisplatin was shown to act by increasing intracellular calcium, triggering a sequential activation of p38MAPK and PKA that results in JNK inhibition and a decrease in the Na+/K+ ATPase activity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.